

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67

April 14, 2025

ISSUE No.
1726

IN THIS ISSUE

In Brief: New Labeling for Once-Monthly Subcutaneous Buprenorphine (*Sublocade*)p 63

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

The Medical Letter®

on Drugs and Therapeutics

Volume 67 (Issue 1726)

April 14, 2025

Take CME Exams

IN BRIEF

New Labeling for Once-Monthly Subcutaneous Buprenorphine (*Sublocade*)

The FDA has approved changes to the labeling of *Sublocade* (Indivior), an extended-release formulation of the partial opioid agonist buprenorphine, to permit faster initiation and use of alternative injection sites. *Sublocade* is indicated for once-monthly subcutaneous treatment of moderate to severe opioid use disorder.¹

Buprenorphine is the maintenance treatment of choice for most patients with opioid use disorder. To prevent severe opioid withdrawal, patients must already be receiving treatment with buprenorphine or undergo a trial with a short-acting transmucosal product before a long-acting formulation can be initiated.² The labeling changes allow for a first subcutaneous dose of *Sublocade* to be given after a single transmucosal test dose of buprenorphine; previously, use of transmucosal buprenorphine for at least 7 days had been required. The new labeling also allows for *Sublocade* to be administered into the abdomen, thigh, buttock, or back of the upper arm; previously, it could only be injected into the abdomen.

Brixadi, another subcutaneous, extended-release formulation of buprenorphine, is already indicated for use following only a single test dose of transmucosal buprenorphine (see Table 1).³

Approval of the new *Sublocade* dosage regimen was based on the results of an open-label trial (available only as an abstract) in which 140 patients were randomized 2:1 to receive *Sublocade* after either a single dose of transmucosal buprenorphine (rapid induction) or 7-14 days of transmucosal treatment (standard induction). The rate of treatment retention at the time of the second injection (1 week after the initial injection), the primary endpoint, was noninferior with rapid induction compared to standard induction (67.1% vs 59.6%). Rates of precipitated opioid

Table 1. *Sublocade* vs *Brixadi*

	<i>Sublocade</i> (Indivior)	<i>Brixadi</i> (Braeburn)
Initial dosage in patients not taking buprenorphine	300 mg SC after transmucosal test dose, then 300 mg 1 week to 1 month later	16 mg SC after transmucosal test dose, then 8 mg up to 3 days later ¹
Target maintenance dosage	100 or 300 mg SC once/month ²	24 or 32 mg SC once/week, or 96 or 128 mg SC q28 days
Administration sites	Abdomen, thigh, buttock, or upper arm	Abdomen, thigh, buttock, or upper arm ³
Storage	Room temperature for up to 12 weeks, or refrigerated	Room temperature
Cost ⁴	\$2117	\$1708

1. If needed during the first week of treatment, an additional 8-mg dose can be given at least 24 hours after the first 8-mg dose.
2. The 300-mg monthly maintenance dose is recommended if patients do not have a satisfactory clinical response to the 100-mg dose.
3. In patients who were not previously receiving buprenorphine, weekly *Brixadi* should not be injected into the upper arm until steady state has been reached (4 consecutive doses); injection in the upper arm is associated with plasma buprenorphine levels ~10% lower than injection in other sites.
4. Approximate WAC for 1 month's treatment with *Sublocade* or 4 weeks' treatment with *Brixadi*. WAC = wholesaler acquisition cost, or manufacturer's published price to wholesalers; WAC represents published catalogue or list prices and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.

withdrawal were similar in the rapid and standard induction groups (16.9% vs 14.6%).⁴

How *Sublocade* and *Brixadi* compare to one another in efficacy is unknown. Use of a long-acting subcutaneous formulation of buprenorphine should reduce the risks of treatment nonadherence and drug diversion, but it is considerably more expensive than sublingual formulations.² ■

1. Once-monthly subcutaneous buprenorphine (*Sublocade*) for opioid use disorder. Med Lett Drugs Ther 2018; 60:35.
2. Drugs for opioid use disorder. Med Lett Drugs Ther 2023; 65:137.
3. Once-weekly or once-monthly subcutaneous buprenorphine (*Brixadi*) for opioid use disorder. Med Lett Drugs Ther 2023; 65:133.
4. R Shiwach et al. A randomized open-label study comparing rapid and standard inductions to injectable buprenorphine extended-release (BUP-XR) treatment. Canadian Society of Addiction Medicine Scientific Congress; Victoria, British Columbia, Canada; October 19-21, 2023. Available at: <http://bit.ly/43Gd3hv>. Accessed March 13, 2025.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:



Copyright 2025. ISSN 1523-2859

